Rege Nephro

Healthcare & Life Sciences

Recent Finacing

Series B

Recent Raise

$151.4M

Rege Nephro Co., Ltd. is a clinical-stage biotech company developing treatments for kidney diseases, including Autosomal Dominant Polycystic Kidney Disease and Chronic Kidney Disease, using technology from Kyoto University's Center for iPS Cell Research and Application.

Total Funding

$44B

Headquarters

Kyoto, Japan

Founded

N/A

Website

regenephro.co.jp

Focus Areas

Biotech

Clinical-stage

Kidney disease

Cell therapy

iPS cell technology

Investors